VIP for Chronic Inflammatory Conditions

Candidate profile

Adults with documented chronic systemic inflammation that has been refractory to conventional management — particularly those with Chronic Inflammatory Response Syndrome (CIRS) from biotoxin exposure (mold, Lyme), chronic respiratory inflammation, or multi-system inflammatory conditions where VIP deficiency has been identified. Also relevant for individuals with post-infectious inflammatory syndromes where immune dysregulation persists after pathogen clearance.

Relevant clinical presentations include:

• CIRS with documented inflammatory biomarker elevation (TGF-beta-1, C4a, MMP-9) after source remediation
• Post-Lyme inflammatory syndrome with persistent cytokine elevation despite antibiotic treatment
• Chronic respiratory inflammation (chronic sinusitis, reactive airway disease) with poor response to conventional therapy
• Mast cell activation syndrome (MCAS) with systemic inflammatory features
• Post-COVID inflammatory syndrome with documented immune dysregulation

Prerequisite: the source of ongoing inflammatory exposure should be identified and remediated before VIP therapy. VIP modulates the immune inflammatory response — it does not remove the stimulus. Using VIP while still exposed to mold, biotoxins, or active infection treats the downstream signal without addressing the cause.

Approach

VIP administration via intranasal or subcutaneous route, leveraging VPAC1 and VPAC2 receptor activation across immune, pulmonary, and neural tissues. VIP is an endogenous 28-amino-acid neuropeptide with potent anti-inflammatory and immunomodulatory properties. It suppresses pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-12), promotes regulatory T-cell differentiation, and protects mucosal barrier integrity — addressing multiple nodes of the chronic inflammatory cascade simultaneously.

Protocol design

Primary peptide: VIP (Vasoactive Intestinal Peptide)

Intranasal protocol (most common for CIRS)

Dose: 50 mcg per spray, 1-2 sprays per nostril

Frequency: 3-4 times daily

Total daily dose: 200-400 mcg

Duration: 30-90 days, depending on clinical response and inflammatory marker normalization

Subcutaneous protocol (for systemic inflammatory conditions)

Dose: 50-100 mcg subcutaneous

Frequency: Once daily

Duration: 4-8 weeks

Note: Subcutaneous VIP requires careful dose titration — rapid VIP administration can cause transient hypotension due to vasodilatory effects. Start at 25-50 mcg and increase over 1-2 weeks.

Administration timing: Morning and midday dosing preferred. VIP has mild vasodilatory effects that some individuals notice as warmth or flushing — this is typically tolerable but may be uncomfortable if it occurs at bedtime.

Reconstitution (for injectable): Reconstitute lyophilized VIP with bacteriostatic water. Standard: 1 mL to a 1 mg vial = 1 mg/mL (1000 mcg/mL). A 100 mcg dose = 0.1 mL. Use insulin syringes for accurate measurement.

Intranasal preparation: VIP nasal spray is typically compounded at 50 mcg/spray by specialty compounding pharmacies. Some practitioners prepare solutions from lyophilized VIP using preservative-free saline for nasal delivery.

Storage: VIP is relatively unstable in solution. Reconstituted VIP should be refrigerated and used within 4 weeks. Avoid repeated freeze-thaw cycles. Intranasal preparations are particularly susceptible to degradation — fresh preparation every 2-3 weeks is optimal.

Expected timeline

Days 1-7: Initial anti-inflammatory signaling begins. Some individuals notice improved respiratory comfort (reduced nasal congestion, easier breathing) within the first few days of intranasal use — this reflects VIP's direct effect on airway smooth muscle and mucosal inflammation. Systemic inflammatory markers have not yet shifted measurably.

Weeks 2-3: Cytokine profile begins normalizing. Pro-inflammatory markers (TNF-alpha, IL-6, TGF-beta-1) may begin declining on repeat testing. Subjective improvements in fatigue, cognitive clarity, and exercise tolerance emerge as the inflammatory burden decreases. Sleep quality often improves as neuroinflammation attenuates.

Weeks 4-6: Measurable inflammatory marker improvement. In CIRS-specific protocols, markers such as MSH, VIP levels, TGF-beta-1, MMP-9, and C4a are tracked. Multi-parameter improvement across these markers is the therapeutic target. Functional capacity continues improving.

Weeks 7-12: Consolidation phase. The immune regulatory effects — particularly regulatory T-cell promotion — require sustained signaling to establish durable immune rebalancing. Some practitioners continue low-dose maintenance (once or twice daily intranasal) for 3-6 months in severe CIRS cases.

Post-cycle assessment: After completing the VIP protocol, monitor inflammatory markers at 4 and 8 weeks post-discontinuation. If markers remain normalized, the immune rebalancing may be durable. If markers begin reverting, a low-dose maintenance protocol (once daily intranasal) or repeat cycle may be necessary. The durability of response often depends on whether upstream triggers (biotoxin exposure, chronic infection) were fully resolved before VIP therapy began.

Concurrent requirements

• Environmental remediation complete: For CIRS, the mold or biotoxin source must be fully remediated. ERMI (Environmental Relative Moldiness Index) testing should confirm remediation success before VIP therapy begins.
• Binder therapy: Cholestyramine, Welchol, or activated charcoal to bind circulating biotoxins. Binders are typically used for 1-3 months before VIP and may continue concurrently.
• MARCoNS treatment: If MARCoNS-positive, treat with BEG spray (Bactroban, EDTA, gentamicin) or equivalent before or concurrent with VIP. LL-37 may be added if BEG spray is insufficient.
• Dietary anti-inflammatory support: Low-amylose diet (Shoemaker recommendation) or Mediterranean-style anti-inflammatory diet. Reduce processed foods, refined sugars, and industrial seed oils that amplify inflammatory signaling.
• Stress management: Chronic inflammation is bidirectionally linked to HPA axis dysfunction. Cortisol dysregulation amplifies inflammatory cytokine production. Stress management (meditation, breathing exercises, sleep optimization) supports the anti-inflammatory environment that VIP therapy targets.

Complementary peptides

• KPV (250 mcg SC daily or oral): Alpha-MSH-derived tripeptide with potent anti-inflammatory effects mediated through NF-kB suppression. Mechanistically complementary to VIP — KPV suppresses the NF-kB inflammatory axis while VIP modulates cytokine production through VPAC receptors. Particularly useful when GI inflammation coexists with systemic inflammation.
• LL-37 (100 mcg SC daily): Cathelicidin-derived antimicrobial peptide. If the chronic inflammation has a biofilm or persistent microbial component (MARCoNS colonization, chronic sinusitis), LL-37 addresses the microbial trigger while VIP addresses the inflammatory response. This combination is common in CIRS protocols.
• Thymosin Alpha-1 (1.6 mg SC 2-3x/week): For immune reconstitution when chronic inflammation has led to immune exhaustion (reduced NK cell function, poor T-cell proliferation). Tα1 rebuilds immune competence while VIP rebalances immune regulation.

Evidence assessment

VIP is an endogenous neuropeptide with extensive basic science literature — over 10,000 publications characterize its anti-inflammatory, immunomodulatory, and neuroprotective properties. Clinical evidence is strongest for pulmonary applications (pulmonary arterial hypertension, sarcoidosis) and CIRS (Dr. Ritchie Shoemaker's published protocols). However, large-scale randomized controlled trials for chronic inflammatory conditions are limited. The mechanism is well-characterized, the endogenous safety profile is inherently favorable (VIP is a normal physiological peptide), and clinical experience in functional medicine is extensive. But the evidence structure is weighted toward case series, open-label studies, and protocol-based clinical experience rather than RCTs.

Monitoring markers

• Inflammatory panel: TGF-beta-1, MMP-9, C4a, C3a, TNF-alpha, IL-6 — baseline, week 4, week 8
• VIP and MSH serum levels (often deficient in CIRS): baseline and week 8
• VEGF levels: assess vascular inflammation
• Pulmonary function: FEV1, FVC if respiratory involvement (spirometry at baseline and week 8)
• Visual Contrast Sensitivity (VCS) testing: neurotoxin-related inflammation tracking
• Fatigue and cognitive function: validated scales (FSS, MoCA) or subjective tracking
• Blood pressure: monitor during dose titration — VIP-induced hypotension is the primary acute side effect
• Subjective symptom tracking: daily log of energy levels, brain fog severity, respiratory comfort, pain levels — use a standardized 1-10 scale for consistency
• Body temperature: low-grade fevers or temperature dysregulation are common in CIRS and may normalize with VIP therapy

Assessment schedule:

• Baseline: complete inflammatory panel, VIP/MSH levels, VCS testing, symptom inventory
• Week 4: first follow-up — inflammatory markers, symptom reassessment, blood pressure trend
• Week 8: comprehensive reassessment — full inflammatory panel, VCS retest, functional capacity evaluation
• Week 12 (if extended protocol): final assessment — determine whether maintenance is needed or discontinuation is appropriate
• 4 weeks post-cycle: retention check — assess whether inflammatory markers remain normalized or begin reverting

Limitations and considerations

• Source remediation first: VIP therapy without removing the inflammatory trigger (mold exposure, biotoxin source) is symptomatic treatment. The Shoemaker CIRS protocol positions VIP as one of the final steps — after binder therapy, MARCoNS treatment, and environmental remediation.
• Hypotension risk: VIP is a vasodilator. Individuals with low baseline blood pressure or autonomic dysfunction (POTS) require conservative dose titration and blood pressure monitoring during initiation.
• Peptide stability: VIP degrades more rapidly in solution than most peptides. Fresh reconstitution, cold storage, and timely use are important for consistent dosing.
• Cost and availability: VIP is one of the more expensive research peptides due to synthesis complexity. Compounding pharmacy sourcing (where legally available) is typical.
• Not a standalone anti-inflammatory: VIP is most effective as part of a comprehensive protocol addressing the underlying cause of inflammation, supporting detoxification, and rebuilding immune function. Isolated VIP use without addressing upstream drivers produces temporary benefit at best.
• Regulatory status: VIP is not FDA-approved for inflammatory conditions. Its use is off-label, typically managed through functional medicine or integrative practitioners experienced with CIRS protocols.
• Diarrhea risk: VIP stimulates intestinal water secretion. Watery diarrhea can occur, particularly at higher doses or with subcutaneous administration. Dose reduction typically resolves this. If diarrhea persists, switch from subcutaneous to intranasal delivery (which provides more gradual systemic levels).
• Tachyphylaxis: Some practitioners report diminishing response with continuous long-term VIP use (beyond 3 months). Periodic cycling (8 weeks on, 4 weeks off) may maintain receptor sensitivity, though this is based on clinical observation rather than controlled data.
• Compounding quality matters: VIP potency and stability vary significantly between compounding pharmacies. Source from pharmacies with documented peptide purity testing and appropriate cold-chain handling. Subpotent VIP preparations are a common cause of treatment failure that gets misattributed to the peptide itself.